Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
izTRAIL, Soluble (human) (rec.)
215
CHF
CHF 215.00
In stock
AG-40B-0069-C01010 µgCHF 215.00
AG-40B-0069-50105 x 10 µgCHF 650.00
| Product Details | |
|---|---|
| Synonyms | Apo-2L; TNFSF10; CD253 |
| Product Type | Protein |
| Properties | |
| Source/Host | E. coli |
| Sequence |
The extracellular domain of human TRAIL (aa 95-281) is fused at the N-terminus to an isoleucine zipper motif. |
| Crossreactivity |
Dog Human |
| Specificity |
Binds to human TRAIL receptors 1-4 (TRAIL-R1 to TRAIL-R4); izTRAIL does not interact with the apoptosis-inducing mouse TRAIL receptor (TRAIL-R). |
| Biological Activity |
Induces apoptosis in vitro in different human cancer cell lines with an EC50 of 5-200ng/ml, depending on the individual cell line used. Recombinant izTRAIL does not kill 4-day cultures of primary human hepatocytes (PHH) at concentrations of at least up to 1μg/ml (Ganten 2006). Good bioavailability in vivo, shows no toxic effects in mice at doses of at least up to 500μg per day (Wissink 2006). |
| MW |
~82kDa as stable trimers (determined by size exclusion chromatography) ~28kDa as monomer (determined by SDS-PAGE) |
| Purity | ≥95% (SDS-PAGE) |
| Endotoxin Content | <0.01EU/μg purified protein (LAL test; Lonza). |
| Concentration | 0.1mg/ml after reconstitution. |
| Reconstitution | Reconstitute with 100μl sterile water. |
| Formulation | Lyophilized. Contains 20mM TRIS-Cl, 0.5M arginine-HCl, 100mM NaCl, 0.02% Tween 20. |
| Other Product Data |
UniProt link P50591: TRAIL (human) |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
izTRAIL is a newly available, highly active recombinant form of soluble human TRAIL. Due to a trimerizing N-terminal isoleucine zipper (iz) motif the intrinsic trimerization of TRAIL, required for apoptosis-inducing activity of TRAIL, is enhanced when compared to non-tagged soluble human TRAIL (shTRAIL). Therefore, izTRAIL is a potent inducer of apoptosis in many human cancer cells, but not normal human hepatocytes. In addition, the half-life of izTRAIL is about eight-fold higher than the half-life of shTRAIL. These properties render izTRAIL highly suitable for both, in vitro and in vivo use, particularly for studies in which investigators plan to transfer their in vitro results into an in vivo system with human cancer cells in xenotransplant settings examining susceptibility to TRAIL-induced apoptosis.
Product References
- Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs: T.M. Ganten, et al.; Clin. Cancer Res. 12, 2640 (2006)
- TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy: E.H. Wissink, et al.; Radiother. Oncol. 80, 214 (2006)
- Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis: R. Koschny, et al.; Clin. Cancer Res. 13, 3403 (2007)
- TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window: R. Koschny, et al.; Hepatology 45, 649 (2007)
- TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells: M.H. Tuthill, et al.; Oncogene 34, 2138 (2015)
- The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2: T. Hartwig, et al.; Mol. Cell 65, 730 (2017)
- Tumour necrosis factor-related apoptosis-inducing ligand induces apoptosis in canine hemangiosarcoma cells in vitro: M. Goto, et al.; Vet. Comp. Oncol. 17, 285 (2019)
- Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors: M. Goto, et al.; J. Vet. Med. Sci. 81, 1791 (2019)
- Pharmacological targeting of TFIIH suppresses KRAS mutant pancreatic ductal adenocarcinoma and synergizes with TRAIL: Cancer Res. 82, 3375 (2022)
Related Products
